Maintaining focus on administering effective malaria treatment during the COVID-19 pandemic

J Raman,1,2,3 PhD; K I Barnes,4 MB ChB, MMed (Clin Pharmacol); L Baker,4 Dip Pharm; M Blaylock,2 MB ChB; L Blumberg,4 MB ChB, MMed (Micro), DTM&H, DOH, DCH; J Frean,1,4 MB ChB, MMed (Path Microbiol); E Misiani,9 PhD, MPH; I S Ukpe,10,11 MB ChB, MMed (Fam Med)

1 Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa
2 Wits Research Institute for Malaria, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
3 University of Pretoria Institute for Sustainable Malaria Control, School of Health Systems and Public Health, University of Pretoria, South Africa
4 Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
5 WorldWide Antimalarial Resistance Network (WWARN), Division of Pharmacology, Faculty of Health Sciences, University of Cape Town, South Africa
6 Amayeza Info Services, Johannesburg, South Africa
7 KwaZulu-Natal Provincial Department of Health, Mangeni, South Africa
8 Faculty of Veterinary Medicine, University of Pretoria, South Africa
9 Malaria and Other Vector-Borne and Zoonotic Diseases Directorate, National Department of Health, Pretoria, South Africa
10 Mpumalanga Provincial Department of Health, Mhondola, South Africa
11 Department of Family Medicine, Faculty of Health Sciences, University of Pretoria, South Africa

Corresponding author: J Raman (jaishreer@nicd.ac.za)

As September marks the start of the malaria season in South Africa (SA), it is essential that healthcare professionals consider both COVID-19 and malaria when a patient who lives in or has recently travelled to a malaria area presents with acute febrile illness. Early diagnosis of malaria by either a rapid diagnostic test or microscopy enables prompt treatment with the effective antimalarial, artemether-lumefantrine, preventing progression to severe disease and death. Intravenous artesunate is the preferred treatment for severe malaria in both children and adults. Adding single low-dose primaquine to standard treatment is recommended in endemic areas to block onward transmission. Use of the highly effective artemisinin-based therapies should be limited to the treatment of confirmed malaria infections, as there is no clinical evidence that these antimalarials can prevent or treat COVID-19. Routine malaria case management services must be sustained, in spite of COVID-19, to treat malaria effectively and support SA’s malaria elimination efforts.

With the current COVID-19 pandemic stretching South Africa (SA)’s already severely overburdened health system to its limits, the prompt diagnosis and urgent treatment of malaria with the most effective therapies has become even more critical. Untreated uncomplicated malaria, particularly infections caused by Plasmodium falciparum in non-immune individuals, rapidly progresses to severe disease (requiring intensive care) and often death. As fever is the primary symptom used for the screening of both malaria and COVID-19 in SA, it is essential that healthcare workers maintain a high index of suspicion for malaria when a patient who lives in or has recently visited a malaria area presents with acute febrile illness. As SA enters the start of the malaria season (September to May), confirming or excluding a malaria infection when faced with such cases of acute febrile illness is now an imperative.

Signs and symptoms

Like those of many infectious diseases prevalent in Africa, the common early-stage clinical features of both malaria and COVID-19 are nonspecific and include fever, headaches, fatigue and sore joints/muscles. In areas where there is a high likelihood of co-infection, confirmatory tests for both diseases should be conducted as soon as possible to inform treatment. In the wake of the COVID-19 pandemic, many healthcare professionals may attribute acute respiratory distress syndrome (ARDS) solely to severe COVID-19 infection. However, it must be borne in mind that young children with malaria and patients with severe, complicated malaria often experience respiratory distress. This overlap in symptoms emphasises the importance of prompt testing for both diseases when patients living in malaria areas or who have recently travelled to a malaria risk area present with ARDS. Levels of certain biomarkers can assist with the differential diagnosis of these two diseases. COVID-19 patients often present with lymphopenia,13 while thrombocytopenia is common in malaria patients.13,19 Although there have been recent reports of raised bilirubin levels in hospitalised patients with COVID-19,14 total bilirubin levels in malaria patients, particularly those with severe malaria, are significantly higher.19 However, some other biochemical changes associated with COVID-19 are also shared with moderate to severe malaria, e.g. raised C-reactive protein14,15 and transaminases.17

Point-of-care diagnosis

Unlike COVID-19, malaria has sensitive antigen-based point-of-care diagnostics that are readily available across the public and private healthcare sectors in SA. Malaria rapid diagnostic tests (RDTs)
Uncomplicated malaria

Despite an increasing prevalence of falciparum parasites resistant to the recommended antimalarial treatment, artemisinin-based combination therapies (ACTs), in the greater Mekong subregion of South-East Asia\(^\text{[12]}\) and in Rwanda in Africa\(^\text{[13]}\), the ACT first introduced into KwaZulu-Natal Province in 2001,\(^\text{[14]}\) artemether-lumefantrine, remains highly efficacious in SA.\(^\text{[15]}\) However, efficacy hinges on ensuring the correct dosage (Table 1), completion of the full treatment course, and ensuring that every dose is taken with at least 1.2 g of fat for optimal absorption of lumefantrine.\(^\text{[16]}\) Currently in SA, artemether-lumefantrine, marketed as Coartem, is registered for use in patients weighing <65 kg, with the Coartem product information leaflet stating that ‘No adequate experience has been acquired in the use of Coartem’ in patients weighing more than 65 kg.\(^\text{[17]}\) As there have been suggestions that patients weighing >85 kg are more susceptible to treatment failure, it is critical to ensure full adherence and fat co-administration in this cohort of patients. For patients weighing >85 kg, extending the treatment course to FIVE days is advised, administering FOUR tablets per dose, given twice daily for a total of 10 doses (off-label recommendation).

In addition, it should be noted that some population groups that are often excluded from clinical trials, such as pregnant women and infants, those with comorbidities (e.g., malnutrition) and/or those taking concomitant medication (e.g., efavirenz, rifampicin), may be at increased risk of suboptimal antimalarial exposure and a poorer response to treatment.\(^\text{[17] - 19]}\) Particularly careful attention should therefore be paid to ensuring their full adherence and monitoring their response to treatment. The use of oral quinine for the treatment of uncomplicated malaria is strongly discouraged, and it should only be used in patients allergic to artemether-lumefantrine.

While ACTs are primarily used to treat falciparum infections, they are highly effective against asexual blood stages of non-falciparum species as well. Non-falciparum infections should be treated with arteether-lumefantrine as for falciparum infections (Table 1). A 14-day course of standard-dose primaquine phosphate (15 mg/d for adults or 0.25 - 0.5 mg base/kg/d) should follow arteether-lumefantrine treatment in children and adults with relapsing malaria (\(P.\) vivax or \(P.\) ovale), including mixed infections. However, primaquine should not be given to infants or to women who are pregnant and/or breastfeeding. Where available, glucose-6-phosphate dehydrogenase (G6PD) status should guide administration of primaquine to prevent relapse. In individuals with confirmed G6PD deficiency, administration of primaquine base at 0.75 mg/kg once a week for 8 weeks, with close medical supervision for potential primaquine-induced adverse haematological effects, is recommended.

Based on the gametocytoidal (transmission-blocking) properties of the antimalarial primaquine, the WHO recommended adding a single low dose of primaquine to ACTs to assist countries attempting to eliminate malaria as well as halt spread of artemisinin-resistant parasites.\(^\text{[21]}\) Unlike the higher doses and longer courses of primaquine required for the radical cure of \(P.\) vivax and \(P.\) ovale malaria, the single low dose of primaquine recommended for transmission blocking is not associated with severe haemolysis in G6PD-deficient individuals.\(^\text{[22]}\) Following local data that confirmed the safety of single low-dose primaquine,\(^\text{[15]}\) the South African Health Products Regulatory Authority approved its use under a section 21A application in selected health facilities in low-transmission malaria endemic districts to support malaria elimination efforts in SA.

Severe malaria

Patients with severe malaria present with a range of clinical signs and symptoms (Table 2). If one (or more) of these features is present, the patient should be treated promptly with intravenous (IV) or intramuscular artesunate (Garson), the recommended treatment for severe malaria in SA. Injectable artesunate was registered for use in SA in June 2017, so section 21 approval for its use to treat severe malaria is no longer required. Treatment outcomes with IV artesunate compared with IV quinine are significantly better in both adults and children,\(^\text{[23]}\) with fatality rates reduced by 39% in adults and 24% in children treated with IV artesunate as opposed to IV quinine.\(^\text{[14]}\) In addition, IV artesunate is more cost-effective, has a simpler dosage regimen (Table 3), is easier to administer, has a better safety profile, and requires no dosage adjustment in renal or hepatic impairment.

Patients with severe malaria should receive at least three doses of IV artemesunate (at 0, 12 and 24 hours), or the treatment should be continued until the patient is well enough to tolerate oral therapy, up to a maximum of 7 days with close monitoring for potential recrudescence. Once the patient is able to swallow, a complete full course (six doses) of arteether-lumefantrine as outlined in Table 1

---

Table 1. Dosing schedule of arteether-lumefantrine

| Body weight | 0 hours | 8 - 12 hours | 24 hours | 36 hours | 48 hours | 60 hours |
|-------------|---------|--------------|----------|----------|----------|----------|
| 5 - <15 kg  | 1 tablet | 1 tablet     | 1 tablet | 1 tablet | 1 tablet | 1 tablet |
| 15 - <25 kg | 2 tablets| 2 tablets    | 2 tablets| 2 tablets| 2 tablets| 2 tablets|
| 25 - <35 kg | 3 tablets| 3 tablets    | 3 tablets| 3 tablets| 3 tablets| 3 tablets|
| 35 - <65 kg | 4 tablets| 4 tablets    | 4 tablets| 4 tablets| 4 tablets| 4 tablets|
| >65 kg*     | 4 tablets| 4 tablets    | 4 tablets| 4 tablets| 4 tablets| 4 tablets|

*For patients weighing >85 kg, extend treatment course to FIVE days, administering FOUR tablets per dose, given twice daily for a total of 10 doses (off-label recommendation).
Severe malaria in pregnancy

As malaria in pregnancy is associated with low-birthweight infants, a heightened risk of anaemia, and an increased risk of severe malaria, pregnancy loss and mortality in low-transmission areas,[26] it is critically important that malaria in pregnancy is treated as a medical emergency. For uncomplicated malaria, ACTs such as artemether-lumefantrine are associated with significantly better treatment outcomes than quinine in all trimesters,[27] and are therefore the recommended treatment in SA.[28] Severe malaria in pregnancy should be preferentially treated with IV artesunate, as pregnant women are at significantly increased risk of quinine-associated hypoglycaemia.[29]

COVID-19 co-infection

Currently there are very limited data on treatment outcomes of malaria patients co-infected with COVID-19. In patients with a mild COVID-19 infection and uncomplicated malaria, we recommend that the standard weight-based six-dose artemether-lumefantrine treatment (Table 1) be administered, with the patient closely monitored to ensure complete parasite clearance. In critically ill patients, IV artesunate should be administered as soon as possible, with parasitaemia levels regularly monitored by microscopy to assess treatment response.

Chloroquine or hydroxychloroquine use should be limited to treatment of inflammatory autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).[30–32] Although initial in vitro data showed that hydroxychloroquine was capable of effectively inhibiting COVID-19,[33,34] these findings have not been replicated in in vivo clinical trial settings. The administration of hydroxychloroquine to patients with mild COVID-19 symptoms did not reduce viral load or the risk of hospitalisation, or shorten the time to complete resolution of symptoms, compared with individuals who received the standard-of-care treatment.[35] In patients with severe COVID-19, hydroxychloroquine administration did not affect intubation or in-hospital mortality rates,[36,37] and was associated with a prolonged QT interval.[38] In addition, the prophylactic effect of hydroxychloroquine against COVID-19 in individuals with SLE and RA has been shown to be negligible.[39] Although chloroquine was previously very effective against falciparum malaria and had a good safety profile,[40] the widespread entrenchedness of chloroquine-resistant falciparum parasites rendered the antimalarial ineffective on the African continent and beyond,[41] necessitating its replacement with ACTs.

Because artemisinin and its derivatives have anti-inflammatory and immune regulatory properties,[42] there have been suggestions

---

**Table 2. Clinical and laboratory features of severe malaria**

| Impaired consciousness. A Glasgow Coma Score <11 in adults or a Blantyre Coma Score <3 in children |
| Prostration. Generalised weakness so that the person is unable to sit, stand or walk without assistance |
| Multiple convulsions. More than two episodes within 24 hours |
| Acidosis. A base deficit >8 mEq/L or, if not available, a plasma bicarbonate level <15 mmol/L or venous plasma lactate ≥5 mmol/L. Severe acidosis manifests clinically as respiratory distress (rapid, deep, laboured breathing) |
| Hypoglycaemia. Blood or plasma glucose <2.2 mmol/L (<40 mg/dL) |
| Severe anaemia. Haemoglobin concentration ≤5 g/dL or a haematocrit ≤15% in children <12 years of age; <7 g/dL and <20%, respectively, in adolescents and adults |
| Renal impairment. Plasma or serum creatinine >265 µmol/L (3 mg/dL) or blood urea >20 mmol/L |
| Jaundice. Plasma or serum bilirubin >50 µmol/L (3 mg/dL) |
| Pulmonary oedema. Radiologically confirmed or oxygen saturation <92% on room air with a respiratory rate >30/min, often with chest indrawing and crepitations on auscultation |
| Significant bleeding. Including recurrent or prolonged bleeding from the nose, gums or venepuncture sites; haematemesis, melaena, haematuria |
| Shock. Compensated shock is defined as capillary refill ≥3 seconds or temperature gradient on leg (mid- to proximal limb), but no hypotension. Decompensated shock is defined as systolic blood pressure <70 mm Hg in children or <80 mm Hg in adults, with evidence of impaired perfusion (cool peripheries or prolonged capillary refill) |
| Hyperparasitaemia. Plasmodium falciparum parasitaemia >4% or >3+ |

**Table 3. Dosing schedule for intravenous artesunate**

| Body weight | Dosing |
|-------------|--------|
| Children <20 kg | 3 mg/kg at 0, 12 and 24 hours then daily until patient is able to tolerate oral treatment, when full 6-dose 3-day artemether-lumefantrine treatment should be given |
| Adult and children ≥20 kg | 2.4 mg/kg at 0, 12 and 24 hours then daily until patient is able to tolerate oral treatment, when full 6-dose 3-day artemether-lumefantrine treatment should be given |
that these drugs can be used to treat COVID-19 infections. However, at present there is no clinical evidence to support any use of artemisinin or any related herbal compounds in either the prevention or the treatment of COVID-19. Use of artemisinin and its derivatives must therefore be restricted to the treatment of malaria infections.

## Conclusions

To ensure that the current COVID-19 pandemic does not result in a major upsurge in malaria cases, derailing SA’s elimination efforts, it is critical that the recommended malaria case management practices and procedures are closely adhered to by all healthcare practitioners. In addition, artemisinin-based therapies must be reserved for the treatment of malaria, as they are only class of antimalarial still effective against falciparum malaria and have no proven effect in either preventing or treating COVID-19.

**Declaration.** None.

**Acknowledgements.** None.

**Author contributions.** JR drafted the manuscript and collated the input provided by KIB, LBa, MB, LBl, JE, EM and ISU. KIB and JR assisted with editing. All authors approved the submission of the final version.

**Funding.** None.

**Conflicts of interest.** None.